Cargando…

Cost comparison of post-remission strategies in younger and older AML patients in France

Detalles Bibliográficos
Autores principales:	Mounie, Michael, Dumas, Pierre-Yves, Liva-Yonnet, Sandra, Fabre, Didier, Leguay, Thibault, Galtier, Jean, Berard, Emilie, Hanta, Ramaroson, Gilleron, Véronique, Bertoli, Sarah, Pigneux, Arnaud, Récher, Christian, Costa, Nadège
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307787/ https://www.ncbi.nlm.nih.gov/pubmed/37380651 http://dx.doi.org/10.1038/s41408-023-00874-y

Ejemplares similares

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Impact des confinements sur les hospitalisations survenues dans un contexte d’usage de substances psycho-actives en France selon l’âge pendant la pandémie de COVID-19
por: Perino, Justine, et al.
Publicado: (2022)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

Hospitalisations après consommation de substances psychoactives pendant la pandémie de COVID-19
por: Dumoulin, Claire, et al.
Publicado: (2023)

Maintenance of elderly AML patients with androgens
por: Pigneux, Arnaud, et al.
Publicado: (2017)

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
por: Récher, Christian, et al.
Publicado: (2021)

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
por: Bérard, Emilie, et al.
Publicado: (2022)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Role of Immunomodulation of BCG Therapy on AML Remission
por: Kennedy, Alice, et al.
Publicado: (2021)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Economic impact of generic antiretrovirals in France for HIV patients’ care: a simulation between 2019 and 2023
por: Demeulemeester, Romain, et al.
Publicado: (2022)

Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France
por: Dumas, Pierre-Yves, et al.
Publicado: (2022)

Association of social deprivation with survival in younger adult patients with AML: an Alliance study
por: Rebechi, Melanie, et al.
Publicado: (2023)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications
por: Fodil, Sofiane, et al.
Publicado: (2022)

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
por: Tsai, Xavier Cheng-Hong, et al.
Publicado: (2023)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis
por: Mottal, Nathan, et al.
Publicado: (2020)

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
por: Berger, Eloïse, et al.
Publicado: (2019)

A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML
por: Wafa, Abdulsamad, et al.
Publicado: (2018)

Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT
por: Hirabayashi, Shigeki, et al.
Publicado: (2021)

Allogeneic stem cell transplantation and minimal residual disease in patients with AML in first complete remission
por: Versluis, Jurjen, et al.
Publicado: (2018)

General hospital admissions in young and middle-aged people who use psychoactive substances: Impact of Covid-19 lockdowns
por: Perino, J, et al.
Publicado: (2023)

Risk factors for length of stay and charge per day differ between older and younger hospitalized patients with AML
por: Kumar, Anita J., et al.
Publicado: (2018)

Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients
por: Pavlovic, Djordje, et al.
Publicado: (2021)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
por: Georgi, Julia-Annabell, et al.
Publicado: (2023)

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
por: Li, Jing, et al.
Publicado: (2023)

Failure to detect autologous antibodies in the remission sera of patients with AML: complications introduced by the presence of rheumatoid factor.
por: James, S. E., et al.
Publicado: (1980)

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dponr3bd2hq1fqet66mav4vr2v